"HemWell - GEN 2" is rolling out!!

Hello to everyone,

I would just like to thank everyone here in the USA, who are helping make our 1st technology "HemWell" (GEN 1) a success. Our new "GEN 2" or 2nd generation device, is now finished and set to commence beta testing in September, with an anticipated market rollout in October 2024. Our focus in 2024 has been the completion of "GEN 2" and scaling the US Market and we could not be happier with the results to date. Our bench testing has already proven "GEN 2" to be a marked advancement, with regards to procedure efficiencies and user / medical provider friendliness.

If your facility is interested in "GEN 2" and/or in becoming a beta test center, please call us directly at: 813-755-6171 or email us at: [email protected]

To our potential Global Partners and Customers and those who have already shown strong interest in "HemWell", we plan on starting to reach out to each of you, in your respective countries, throughout 2025 and 2026.

Thank you and I look forward to meeting you all in person, soon.

Kind regards,

Michael J. Goeree

Founder & Chairman

and

Dr. Stephen A. Goldman, MD

Founder & Chief Medical Officer

Medfiniti International, Inc.

www.medfiniti.com

www.hemwellmd.com